Form 8-K - Current report:
SEC Accession No. 0000950123-21-010438
Filing Date
2021-08-12
Accepted
2021-08-12 08:31:43
Documents
14
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d167509d8k.htm   iXBRL 8-K 22903
2 EX-99.1 d167509dex991.htm EX-99 73509
3 GRAPHIC g167509g12e95.jpg GRAPHIC 5123
  Complete submission text file 0000950123-21-010438.txt   239791

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20210812.xsd EX-101.SCH 2915
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20210812_lab.xml EX-101.LAB 18887
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20210812_pre.xml EX-101.PRE 11875
7 EXTRACTED XBRL INSTANCE DOCUMENT d167509d8k_htm.xml XML 3478
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 211165601
SIC: 2836 Biological Products, (No Diagnostic Substances)